2025-10-21T15:40:43+00:00 2024-12-31 346565596 ERNST & YOUNG US LLP 101 E WASHINGTON ST PHOENIX AZ 85004 990 2024-01-01 271120123 Creative Testing Solutions CREA 6023437016 2424 W ERIE DR TEMPE AZ 852823133 Tanya Perry CFO 2077120357 2025-10-21 true true Steven T Rutti P00775456 6023223000 2025-10-19 2024 2025-03-06 01:10:19Z SALLY CHOI 2424 W ERIE DR TEMPE AZ 852823133 501961859 false X WWW.MYCTS.ORG X 2009 AZ TO PROVIDE EXCEPTIONAL CUSTOMIZED LABORATORY TESTING SERVICES TO SUPPORT THE HOSPITALS AND OTHER HEALTHCARE ORGANIZATIONS WITH THEIR LIFE SAVING MISSIONS. 11 11 1236 11 0 0 0 493111263 492015169 425598 3382436 0 0 493536861 495397605 0 0 0 0 100718465 102062411 0 0 0 330516513 336134025 431234978 438196436 62301883 57201169 257226269 238533836 99550256 95429009 157676013 143104827 TO PROVIDE EXCEPTIONAL CUSTOMIZED LABORATORY TESTING SERVICES TO SUPPORT THE HOSPITALS AND OTHER HEALTHCARE ORGANIZATIONS WITH THEIR LIFE SAVING MISSIONS. false false 403261228 0 488039024 DONOR TESTING BLOOD DONOR AND PLASMA TESTING SERVICES PROVIDED BY CREATIVE TESTING SOLUTIONS ("CTS") ARE ESSENTIAL TO ENSURING THE SAFETY OF THE NATION'S BLOOD AND PLASMA SUPPLY. THESE TESTING ACTIVITIES ARE ABSOLUTELY NECESSARY AND MANDATED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION ("FDA") TO PROVIDE A SAFE BLOOD PRODUCT FOR TRANSFUSION TO PATIENTS AND TO ENSURE SAFETY OF PLASMA PRODUCTS. DUE TO THE SIGNIFICANT HEALTH RISKS ASSOCIATED WITH THE USE OF HUMAN BLOOD AND BLOOD COMPONENTS, IT IS CRITICAL FOR PUBLIC SAFETY PURPOSES THAT BLOOD BE PROPERLY TESTED BEFORE BEING INTRODUCED INTO THE HEALTHCARE SYSTEM FOR USE BY PATIENTS. A SAFE BLOOD SUPPLY IS CRITICAL TO THE WELL-BEING OF THE NATION'S HEALTHCARE SYSTEM AND ITS PATIENTS. THE SIGNIFICANCE OF THE TESTING OF BLOOD FOR PUBLIC SAFETY IS EVEN MORE PRONOUNCED IN THIS AGE OF THREATS FROM PANDEMICS AND TERRORISM. CREATIVE TESTING SOLUTIONS OPERATED EIGHT DONOR TESTING LABORATORIES IN 2024. OUR FIRST ESTABLISHED LABORATORY IS IN TEMPE, ARIZONA. THE ADDITIONAL LABORATORIES ARE LOCATED IN BEDFORD, TEXAS, CHARLOTTE, NORTH CAROLINA, ST. LOUIS, MISSOURI, ST. PETERSBURG, FLORIDA, SAN MARCOS, TEXAS, AUSTIN, TEXAS, AND MEMPHIS, TENNESSEE. THESE LOCATIONS ARE STRATEGICALLY POSITIONED NEAR MAJOR AIRPORTS IN PHOENIX, DALLAS, CHARLOTTE, ST. LOUIS AND TAMPA. THE FIVE DTL LABORATORIES ARE FOOD AND DRUG ADMINISTRATION (FDA) REGISTERED FACILITIES AND HOLD CURRENT CERTIFICATIONS FOR THE CLINICAL LABORATORY IMPROVEMENT ACT (CLIA) AS WELL AS ACCREDITATION WITH THE AMERICAN ASSOCIATION OF BLOOD BANKS (AABB), THE NEW YORK STATE DEPARTMENT OF HEALTH, CALIFORNIA DEPARTMENT OF HEALTH SERVICES AND STATE OF FLORIDA AGENCY FOR HEALTH CARE ADMINISTRATION. IN ADDITION TO DONOR SPECIMEN TESTING, THE LABORATORIES PARTICIPATE IN CLINICAL EVALUATION OF REAGENTS, TEST KITS, AND EQUIPMENT. CTS PROVIDES THE HIGHEST QUALITY IN TESTING AND SERVICE. THE LABORATORIES MAINTAIN INTERNAL QUALITY CONTROL PROGRAMS AND PARTICIPATE VOLUNTARILY IN EXTERNAL QUALITY CONTROL PROGRAMS. BLOOD SPECIMENS ARE PROCESSED UTILIZING STATE OF THE ART TECHNOLOGY WITH FDA LICENSED TEST KITS AND REAGENTS. ALL LABORATORIES ARE EQUIPPED WITH MULTIPLE AND REDUNDANT INSTRUMENTS REQUIRED FOR ROUTINE PROCESSING. ADDITIONALLY, EACH FACILITY ACTS AS A BACKUP LABORATORY TO THE OTHER CTS LABS. SPECIAL TESTING OUR SPECIAL TESTING LABORATORY IN THE PHOENIX AREA PERFORMS CONFIRMATORY AND SUPPLEMENTAL TESTING OF DONOR SAMPLES AS WELL AS NON-DONATION TESTING SUCH AS DONOR RE-ENTRY, POST EXPOSURE AND DONOR FOLLOW-UP. IT ALSO PROVIDES TESTING FOR EYE BANKS, TISSUE BANKS AND CORD BLOOD CENTERS. THE SPECIAL TESTING LABORATORIES ALSO COMPLY WITH CLIA, FDA, CA, NY, MD, AND FL STATE REGULATIONS. COMPONENT QUALITY CONTROL OUR COMPONENT QUALITY CONTROL LABORATORY IN PHOENIX PROVIDES BLOOD COMPONENT QUALITY CONTROL TESTING. RESIDUAL WHITE BLOOD CELL (RWBC) COUNTS ARE PERFORMED ON LEUKOREDUCED PRODUCTS. FACTOR VIII AND FIBRINOGEN ASSAYS ARE PERFORMED ON CRYOPRECIPITATE AND PLASMA PRODUCTS. BACTERIA DETECTION IS PERFORMED ON APHERESIS PLATELETS. 2128960 0 3976145 RESEARCH AND DEVELOPMENT THE CTS RESEARCH PROGRAM IS DEDICATED TO ADVANCING BLOOD SAFETY AND EVIDENCE-BASED TRANSFUSION PRACTICES THROUGH SCIENTIFIC RESEARCH. THE CTS RESEARCH PROGRAM FOCUSES ON THE DEVELOPMENT AND/OR EVALUATION OF NEW BLOOD DONOR SCREENING TECHNOLOGIES WHICH SIGNIFICANTLY IMPROVE AND PROMOTE BLOOD SAFETY IN THE AREAS OF INFECTIOUS DISEASE, IMMUNOLOGY, MOLECULAR DIAGNOSTICS, AND EPIDEMIOLOGY. ADDITIONALLY, THE CTS RESEARCH PROGRAM SERVES AS THE FOCUS FOR A MULTI-INSTITUTIONAL CONSORTIUM WHICH COLLECTS AND INTEGRATES TESTING DATA FROM A SIGNIFICANT PORTION OF THE US BLOOD SUPPLY FOR THE PURPOSE OF NATIONAL HAEMOVIGILANCE, HORIZON SCANNING FOR EMERGING INFECTIOUS DISEASES RELEVANT TO BLOOD SAFETY, AND PROVIDING CRITICAL INFORMATION FOR THE EVALUATION OF BEST PRACTICES IN TRANSFUSION MEDICINE, THE PROMOTION OF DONOR HEALTH, AND THE IMPROVEMENT OF TRANSFUSION RECIPIENT OUTCOMES. 405390188 true false false false false false false false false false true false false true true true true false false false false false false false false false false false false true false false false false false false false false false false false false false false true false false false false false true 85 0 true 1236 true false false false false false false true false X 11 11 false false false false true true true true true false false false true true true true true true true true false false CA X TANYA PERRY 4802168206 2424 W ERIE DR TEMPE AZ 85282 NORMA SUTTON DIRECTOR/VICE-CHAIR 1.0 0.0 X X 0 0 0 Patricia ABREGO-SANTUCCI DIRECTOR/SECRETARY 1.0 0.0 X X 0 0 0 RON WAECKERLIN MD DIRECTOR/CHAIR 1.0 0.0 X X 0 0 0 ALLAN GOLDBERG DIRECTOR (THRU 01/24) 1.0 0.0 X 0 0 0 BRIAN HAMIL DIRECTOR 1.0 0.0 X 0 0 0 CHRIS HROUDA DIRECTOR 1.0 0.0 X 0 0 0 CRAIG MENDELSOHN DIRECTOR 1.0 0.0 X 0 0 0 DAVID GREEN DIRECTOR 1.0 0.0 X 0 0 0 GEORGE SCHOLL DIRECTOR 1.0 0.0 X 0 0 0 KATHY WALDMAN DIRECTOR 1.0 0.0 X 0 0 0 PAUL SULLIVAN DIRECTOR (AS OF 04/24) 1.0 0.0 X 0 0 0 ROBERT S COLE DIRECTOR 1.0 0.0 X 0 0 0 JEFFREY MODELL CHIEF INFORMATION OFFICER 45.0 0.0 X 579823 0 53585 PHILIP WILLIAMSON PHD CHIEF OPERATING OFFICER 45.0 0.0 X 683367 0 51719 SALLY CHOI PRESIDENT/CEO 45.0 0.0 X 1130047 0 52026 TANYA PERRY CHIEF FINANCIAL OFFICER 45.0 0.0 X 672374 0 41863 Chad Westhoven VP, QUALITY IMPROVEMENT 45.0 0.0 X 337965 0 44418 Elizabeth Davis VP, Human Resources 45.0 0.0 X 295953 0 49356 Josh Moon Senior Director, Automation 45.0 0.0 X 221076 0 42648 Leilani Palmer VP, Operations 45.0 0.0 X 329628 0 25474 MARION LANTERI VP, SCIENTIFIC AFFAIRS 45.0 0.0 X 354205 0 19875 MELINDA BRYANT SENIOR DIRECTOR, STRATEGIC INITIATIVES 45.0 0.0 X 236752 0 26658 NANCY HAUBERT VP, SOURCE PLASMA OPERATIONS 45.0 0.0 X 322036 0 29533 AUDREY LOVE DIRECTOR, OPERATIONS II 45.0 0.0 X 282286 0 21900 JANE HIPPISLEY DIRECTOR, OPERATIONS II 45.0 0.0 X 284594 0 25696 Lisa Crawford Associate VP, Project Leader 45.0 0.0 X 305265 0 38355 Sheryl Cyrus DIRECTOR, OPERATIONS II 45.0 0.0 X 280973 0 40089 SUBHASH PARAMESWARAN SENIOR DIRECTOR, APPLICATIONS 45.0 0.0 X 281908 0 25569 6598252 0 588764 168 false true true CISSELL MUELLER CONSTRUCTION INC 5530 SALT RIVER ROAD ST PETERS MO 63373 CONSTRUCTION SERVICES 3992240 Harman Connected Services 447 Indio Way Sunnyvale CA 94085 CONSULTING SERVICES 2409332 Wellsky Corporation 11300 Switzer Road Overland Park KS 66210 SOFTWARE SUBSCRIPTION SERVICES 1104655 Workday Inc 6110 STONERIDGE MALL ROAD PLEASANTON CA 94588 SOFTWARE SUBSCRIPTION SERVICES 974996 STARLIMS Corporation 4000 Hollywood Boulevard Suite 333 South Hollywood FL 33021 CONSULTING SERVICES 952867 27 0 0 0 0 0 0 0 0 LABORATORY SERVICES 621500 488039024 488039024 0 0 RESEARCH & DEVELOPMENT 621500 3976145 3976145 0 0 0 0 0 0 492015169 3220083 3220083 0 0 6137634 588973 5821030 743224 316604 -154251 162353 162353 0 0 0 0 0 0 495397605 492015169 0 3382436 0 0 7193707 7193707 76526884 67834296 8692588 12003308 9721119 2282189 6338512 5301161 1037351 1100918 282691 818227 452888 452888 145285 145285 117562 117562 2963532 779018 2184514 0 1523818 1377410 146408 7389671 66174 7323497 20153145 19950640 202505 806186 317679 488507 5499408 5025269 474139 1107089 1107089 OPERATING & TESTING SUPPLIES 277290388 277290388 FREIGHT/SAMPLE TRANSPORTATION 11954882 11941648 13234 EQUIP. LEASE, REPAIR, & MAIN 5427998 5421794 6204 ALL OTHER EXPENSES 201255 80901 120354 0 0 0 0 438196436 405390188 32806248 0 56219507 58537917 93336376 72617409 0 0 0 0 3795374 3352159 2414938 4559053 69435029 24561713 41134103 44873316 28565576 30092940 0 0 31760395 24501042 257226269 238533836 67946211 71027967 0 0 31604045 24401042 99550256 95429009 X 157676013 143104827 157676013 143104827 257226269 238533836 X 57201169 427645 -72200000 X false true true false X 1214452 1214452 24573889 749003 23824886 3726783 2504178 1222605 37537914 21308532 16229382 2381991 2381991 44873316 Right of use assets 23343928 Other Assets 1157114 24501042 Federal Income Taxes Operating lease obligations 23343928 Deferred comp liability 1057114 24401042 X 496042398 427645 334710 762355 495280043 117562 0 117562 495397605 438413584 334710 334710 438078874 117562 0 117562 438196436 Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote As of December 31, 2024, the Company evaluated whether it had uncertain tax positions that should be recognized or derecognized based on a 'more likely than not' threshold for tax positions taken or expected to be taken in a tax return, including those tax positions that would not be sustained upon examination in accordance with guidance related to Accounting Standards Codification (ASC) 740, Accounting for Uncertainty in Income Taxes. The tax years for the Company that are open to audit by the IRS and state departments of revenue are the tax years ended December 31, 2021, through the current tax year except in certain states where the open tax years generally begin with the tax year ended December 31, 2020. As of December 31, 2024, the Company has not identified any uncertain tax positions that would require the recording of a tax liability. Schedule D, Part XI, Line 2(d) Other revenues in audited financial statements not in form 990 NON-OPERATING WRITE-OFFS - 334710 Schedule D, Part XII, Line 2(d) Other expenses in audited financial statements not in form 990 NON-OPERATING WRITE-OFFS - 334710 X true true X X X X X X false true false false false false false true false JEFFREY MODELL CHIEF INFORMATION OFFICER 360023 0 210200 0 9600 0 18740 0 34845 0 633408 0 0 0 PHILIP WILLIAMSON PHD CHIEF OPERATING OFFICER 428167 0 245600 0 9600 0 29067 0 22652 0 735086 0 0 0 SALLY CHOI PRESIDENT/CEO 663000 0 442700 0 24347 0 30750 0 21276 0 1182073 0 13647 0 TANYA PERRY CHIEF FINANCIAL OFFICER 393178 0 231200 0 47996 0 27335 0 14528 0 714237 0 38396 0 Chad Westhoven VP, QUALITY IMPROVEMENT 263165 0 65200 0 9600 0 12857 0 31561 0 382383 0 0 0 Elizabeth Davis VP, Human Resources 230563 0 55790 0 9600 0 15200 0 34156 0 345309 0 0 0 Leilani Palmer VP, Operations 257428 0 62600 0 9600 0 12904 0 12570 0 355102 0 0 0 MARION LANTERI VP, SCIENTIFIC AFFAIRS 276805 0 67800 0 9600 0 8263 0 11612 0 374080 0 0 0 MELINDA BRYANT SENIOR DIRECTOR, STRATEGIC INITIATIVES 190089 0 46663 0 0 0 11894 0 14764 0 263410 0 0 0 NANCY HAUBERT VP, SOURCE PLASMA OPERATIONS 253097 0 61439 0 7500 0 16008 0 13525 0 351569 0 0 0 Josh Moon Senior Director, Automation 170494 0 41345 0 9237 0 11395 0 31253 0 263724 0 0 0 AUDREY LOVE DIRECTOR, OPERATIONS II 219836 0 54950 0 7500 0 6567 0 15333 0 304186 0 0 0 JANE HIPPISLEY DIRECTOR, OPERATIONS II 219473 0 57621 0 7500 0 14214 0 11482 0 310290 0 0 0 Sheryl Cyrus DIRECTOR, OPERATIONS II 218411 0 55062 0 7500 0 14381 0 25708 0 321062 0 0 0 SUBHASH PARAMESWARAN SENIOR DIRECTOR, APPLICATIONS 226962 0 54946 0 0 0 14080 0 11489 0 307477 0 0 0 Lisa Crawford Associate VP, Project Leader 235024 0 70241 0 0 0 14237 0 24118 0 343620 0 0 0 Schedule J, Part I, Line 1a Housing allowance or residence for personal use JOSH MOON RECEIVED A HOUSING ALLOWANCE TO SUPPORT RELOCATING. THE BENEFIT IS TREATED AS TAXABLE COMPENSATION TO THE INDIVIDUAL. Schedule J, Part I, Line 4b Supplemental nonqualified retirement plan CERTAIN EMPLOYEES PARTICIPATE IN A SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN. THE FOLLOWING INDIVIDUALS EXPERIENCED A TAXABLE VESTING EVENT RELATED TO THIS PLAN DURING THE YEAR. THESE AMOUNTS WERE INCLUDED IN COLUMN (B)(III) AS TAXABLE WAGES. ANY PORTION THAT WAS PREVIOUSLY REPORTED ON A PRIOR 990 AS DEFERRED HAS BEEN REPORTED IN COLUMN (F). SALLY CHOI: $13,647 TANYA PERRY: $38,396 Schedule J, Part I, Line 7 Non-fixed payments CREATIVE TESTING SOLUTIONS HAS AN INCENTIVE PLAN FOR MANAGEMENT AND EXECUTIVES. AWARDS UNDER THE PLAN ARE AT THE DISCRETION OF THE BOARD OF DIRECTORS. THE PLAN MEASURES PERFORMANCE AGAINST MULTIPLE METRICS, WHICH CARRY VARIOUS WEIGHTINGS, INCLUDING NET MARGIN AND CUSTOMER SERVICE. THE INCENTIVE PLAN IS DESIGNED AND APPROVED BASED ON THE RECOMMENDATIONS OF THE INDEPENDENT COMPENSATION CONSULTANT RETAINED BY THE BOARD OF DIRECTORS. Form 990, Part VI, Line 6 Classes of members or stockholders CREATIVE TESTING SOLUTIONS HAD THREE NONPROFIT MEMBERS IN 2024: THE AMERICAN NATIONAL RED CROSS (40%), ONEBLOOD, INC. (20%) AND VITALANT (40%). Form 990, Part VI, Line 7a Members or stockholders electing members of governing body VITALANT SHALL BE ENTITLED TO DESIGNATE 4 DIRECTORS. THE AMERICAN NATIONAL RED CROSS SHALL BE ENTITLED TO DESIGNATE 4 DIRECTORS. ONEBLOOD SHALL BE ENTITLED TO DESIGNATE 3 DIRECTORS. Form 990, Part VI, Line 7b Decisions requiring approval by members or stockholders CERTAIN ACTIONS AND DECISIONS OF THE CORPORATION REQUIRE PRIOR UNANIMOUS APPROVAL FROM MEMBERS PER THE BYLAWS. Form 990, Part VI, Line 11b Review of form 990 by governing body THE FORM 990 IS PREPARED BY AN OUTSIDE ACCOUNTING FIRM BASED ON INFORMATION PROVIDED BY THE CFO AND THE FINANCE TEAM. A COPY OF THE DRAFT FORM 990 AND SCHEDULES IS SUPPLIED TO ALL BOARD MEMBERS PRIOR TO THE MEETING HELD TO APPROVE THE FILING OF THE RETURNS. MEMBERS OF MANAGEMENT REVIEW THE FORM 990 WITH THE BOARD AND ARE AVAILABLE FOR ANSWERING QUESTIONS. ANY COMMENTS FROM THE BOARD ARE CONSIDERED PRIOR TO FILING THE FORM 990 WITH THE IRS. Form 990, Part VI, Line 12c Conflict of interest policy EACH YEAR, THE BOARD OF DIRECTORS, OFFICERS AND SENIOR MANAGEMENT ARE REQUIRED TO SIGN AND RETURN A CONFLICT OF INTEREST FORM TO COMPANY COUNSEL AND ATTEST TO COMPLIANCE WITH THE BOARD'S CONFLICT OF INTEREST POLICY. ANY CONFLICTS DISCLOSED ARE DISCUSSED WITH THE BOARD AND RESOLVED. IN ADDITION, IN PREPARATION FOR THE FORM 990 FILING, THE DIRECTORS, OFFICERS AND KEY EMPLOYEES IDENTIFIED ARE REQUIRED TO RESPOND TO A COMPREHENSIVE CONFLICT OF INTEREST AND FAMILY RELATIONSHIP QUESTIONNAIRE. ANY CONFLICTS DISCLOSED ARE DISCUSSED WITH THE BOARD AND DISCLOSED APPROPRIATELY ON THE FORM 990. Form 990, Part VI, Line 15a Process to establish compensation of top management official THE BOARD OF DIRECTORS HIRES AN INDEPENDENT CONSULTING FIRM ONCE EVERY 2-3 YEARS TO PROVIDE DATA ON COMPETITIVENESS OF SALARIES AND BENEFITS FOR THE CEO, OTHER OFFICERS, AND KEY EMPLOYEES OF THE CORPORATION. THIS PROCESS WAS LAST COMPLETED IN MARCH 2025. THE HUMAN RESOURCE DEPARTMENT COLLECTS INFORMATION THROUGH SURVEYS AND OTHER SOURCES IN ADDITION TO THE INDEPENDENT CONSULTING FIRM. NO MEMBERS OF THE BOARD ARE MEMBERS OF THE CORPORATION'S MANAGEMENT. COMPENSATION FOR THESE INDIVIDUALS IS SET AND APPROVED BY THE BOARD EACH YEAR. THE RESULTS OF THESE DISCUSSIONS, REVIEWS AND APPROVALS ARE DOCUMENTED IN THE EXECUTIVE SESSION MINUTES OF THE BOARD MEETINGS. Form 990, Part VI, Line 15b Process to establish compensation of other employees THE ORGANIZATION HIRED AN OUTSIDE CONSULTING FIRM IN 2022 TO PERFORM A COMPLETE MARKET ANALYSIS FOR ALL POSITIONS, INCLUDING KEY EMPLOYEES. Form 990, Part VI, Line 19 Required documents available to the public UPON REQUEST, THE FORM 990 CAN BE PRINTED OR VIEWED ON-LINE. UPON WRITTEN REQUEST TO THE CHIEF FINANCIAL OFFICER, A COPY OF THE FORM 990 WILL BE MAILED TO THE REQUESTOR. Form 990, Part XI, Line 9 Other changes in net assets or fund balances DISTRIBUTION TO MEMBERS - -72200000; GENESIS GLOBAL PURCHASING ORGANIZATION 2424 W Erie Dr Tempe AZ 85282 844212779 PURCHASING AZ 157528 1214880 CTS